My watch list
my.bionity.com  
Login  

1,688 Newest Publications in british journal of clinical pharmacology

rss

You can refine your search further. Select from the filter options on the left to narrow down your results.

Issue Information

22-Jan-2018 | British Journal of Clinical Pharmacology, 2018

No abstract is available for this article.

more

INFLUENCE OF PHARMACOGENETIC POLYMORPHISMS AND DEMOGRAPHIC VARIABLES ON METFORMIN PHARMACOKINETICS IN AN ADMIXED BRAZILIAN COHORT

20-Jan-2018 | Ana Beatriz Santoro, Mariana Rodrigues Botton, Claudio José Struchiner, Guilherme Suarez‐Kurtz, British Journal of Clinical Pharmacology, 2018

Abstract Aim To identify pharmacogenetic and demographic variables that influence the systemic exposure to metformin in an admixed Brazilian cohort. Methods The extreme discordant phenotype was used to select 106 data sets from nine metformin bioequivalence trials, comprising 256 ...

more

Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations

20-Jan-2018 | Eden C. Andrew, Nigel Curtis, Ben Coghlan, Noel Cranswick, Amanda Gwee, British Journal of Clinical Pharmacology, 2018

Abstract Aim Lipid formulations of amphotericin B, rather than conventional amphotericin (c‐amB), are increasingly used despite limited data comparing these preparations in children. Data on the incidence of adverse effects with amphotericin‐B at standard doses are scarce. This study aimed ...

more

Drug Promotion Practices: A review

19-Jan-2018 | Nilan T. Jacob, British Journal of Clinical Pharmacology, 2018

Abstract Over the years, the pharmaceutical industry has been at the forefront of research and innovation in drug discovery and development. The process of drug discovery extending from pre‐clinical studies to multi‐centric clinical trials and post‐marketing phase is a costly affair running ...

more

Drug Promotion Practices: A review

19-Jan-2018 | Nilan T. Jacob, British Journal of Clinical Pharmacology, 2018

Abstract Over the years, the pharmaceutical industry has been at the forefront of research and innovation in drug discovery and development. The process of drug discovery extending from pre‐clinical studies to multi‐centric clinical trials and post‐marketing phase is a costly affair running ...

more

First in human study to assess safety, pharmacokinetics and pharmacodynamics of BMS‐962212, a direct, reversible, small molecule factor XIa inhibitor in non‐Japanese and Japanese healthy subjects

19-Jan-2018 | Vidya Perera, Joseph M. Luettgen, Zhaoqing Wang, Charles E. Frost, Cynthia Yones, Cesare Russo, John Lee, Yue Zhao, ..., British Journal of Clinical Pharmacology, 2018

Abstract Aims To assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of BMS‐962212, a first‐in‐class Factor XIa inhibitor, in Japanese and non‐Japanese healthy subjects. Methods This was a randomized, placebo‐controlled, double‐blind, sequential, ascending dose study of ...

more

Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor Simeprevir and frequently used concomitant medications

18-Jan-2018 | Fiona Marra, Christoph Höner zu Siederdissen, Saye Khoo, David Back, Michael Schlag, Sivi Ouwerkerk‐Mahadevan, Ceyhu ..., British Journal of Clinical Pharmacology, 2018

Aims Direct‐acting antivirals (DAAs) for the treatment of hepatitis C (HCV) can be associated with drug‐drug interactions (DDIs) with concomitant medications. The practical clinical implications of such DDIs are poorly understood. We assessed the clinical impact of possible pharmacokinetic ...

more

The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool

17-Jan-2018 | Daniel F.B. Wright, Nicola Dalbeth, Amanda J. Phipps‐Green, Tony R. Merriman, Murray L. Barclay, Jill Drake, Paul Ta ..., British Journal of Clinical Pharmacology, 2018

ABSTRACT This research aims to evaluate the predictive performance of a published allopurinol dosing tool. Allopurinol dose predictions were compared to the actual dose required to achieve serum urate (SU) ‐1 using mean prediction error. The influence of patient factors on dose predictions was ...

more

Better characterization of vinflunine pharmacokinetics variability and exposure/toxicity relationship to improve its use: analyses from 18 trials

17-Jan-2018 | A. Schmitt, L. Nguyen, G. Zorza, P. Ferré, A. Pétain, British Journal of Clinical Pharmacology, 2018

Summary Aims Vinflunine is a novel tubulin‐targeted inhibitor indicated as a single agent for the treatment of bladder cancers after failure of prior platinum‐based therapy. Its pharmacokinetics (PK) and pharmacodynamics (PD) have been independently characterized through several phase I and ...

more

Pharmacokinetic/pharmacodynamic drug‐drug interactions of avatrombopag when co‐administered with dual or selective CYP2C9 and CYP3A interacting drugs

17-Jan-2018 | Maiko Nomoto, Cynthia A. Zamora, Edgar Schuck, Peter Boyd, Min‐Kun Chang, Jagadeesh Aluri, Y. Amy Siu, W. George Lai ..., British Journal of Clinical Pharmacology, 2018

Summary Aims Avatrombopag, a thrombopoietin receptor agonist, is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A. We assessed three drug‐drug interactions of avatrombopag as a victim with dual or selective CYP2C9/3A inhibitors and inducers. Methods This was a 3‐part, open‐label ...

more

Page 1 From 169
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE